Definitive Contract 75N91018C00007
Award Date
6/1/18
Potential Completion Date
1/29/24
Potential Value
$6.9M
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for $2,293,892.00. The contract is for laboratory testing services and does not have a set-aside designation. ABL is a foreign-owned, for-profit manufacturer of goods that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. In addition to this contract, ABL holds...
This is a definitive contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The $4,712,200.49 cost-plus-fixed-fee contract supports research on retroviral pathogenesis, treatment, and prevention. It has an ultimate completion date of November 30, 2014 and does not have a set-aside designation. ABL has significant expertise in biologics...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL) for the production of HCMV-TR3ΔPP71 HIVGAG for clinical trials, as part of NIAID's Preclinical Development Support program. The contract has a ceiling value of $7,930,251.64 and a period of performance ending on June 30, 2025. ABL, a for-profit...
This is a $2,696,523.00 delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer, for NIAID's Preclinical Development Support program. The contract has a period of performance through December 31, 2026 and is a cost-plus-fixed-fee type. ABL, a leading contract research and manufacturing organization, provides a range of preclinical and clinical development services to support...
This is a $3,500 firm-fixed-price delivery order awarded to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. The order is under the NIAID's Diagnostics Pre-Clinical Services Program Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $24 million. ABL, a foreign-owned, for-profit manufacturer, is providing a range of preclinical development services to support...
This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...
This is a $6,095,159.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) for expertise in professional pharmaceutical project management. The contract is issued under the larger Resources to Advance Pediatrics and HIV Prevention Science indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL, a manufacturer of biologics including vaccines and monoclonal antibodies,...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for R&D and medical support services related to AIDS research. The contract has a ceiling value of $2,857,610.47 and a period of performance through August 29, 2024. This award is not associated with a set-aside program. ABL, a foreign-owned, for-profit...
This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned for-profit manufacturer of goods. The $8,997,298.00 contract supports the production of ALVAC-HIV drug product and diluent as part of NIAID's Preclinical Development Support program. ABL, a contract research and manufacturing...
This federal contract award, valued at $3,500.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) under the Diagnostics Pre-Clinical Services Program Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The contract has a period of performance through June 19, 2030 and is a Firm Fixed Price delivery order. ABL, a foreign-owned, for-profit manufacturer of goods, will provide a range of preclinical services to...